MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jog.70476

Медицинская библиотека · The journal of obstetrics and gynaecology research · 2026

Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2023 and Annual Treatment Report for 2018.

Kajiyama Hiroaki, Tamauchi Satoshi, Takahashi Fumiaki, Satoh Toyomi, Board members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology

СтатьяПеревод в очереди

Аннотация

AIM: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2023 and the Annual Treatment Report for 2018 on the outcomes of patients who started treatment in 2018.

METHODS

The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2023 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2018 was analyzed by using the Kaplan-Meier, log-rank, and Wilcoxon tests.

RESULTS

Treatment was initiated in 2023 for 8061 patients with cervical cancer, 15 455 with endometrial cancer, 8844 with ovarian, tubal, and peritoneal cancer, 2316 with ovarian borderline tumors, and with the others (230 vulvar cancer, 157 vaginal cancer, 533 uterine sarcoma, 54 uterine adenosarcoma, 132 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2018 were as follows. For cervical cancer, the rates were 92.6%, 75.7%, 57.3%, and 25.9% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.3%, 88.3%, 75.2%, and 32.1% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 90.9%, 79.2%, 53.4%, and 41.1% for Stages I, II, III, and IV, respectively.

CONCLUSION

The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

Для цитирования: Kajiyama Hiroaki, Tamauchi Satoshi, Takahashi Fumiaki, Satoh Toyomi, Board members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2023 and Annual Treatment Report for 2018.. The journal of obstetrics and gynaecology research. 2026. DOI: 10.1111/jog.70476.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.